Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Medroxyprogesterone acetate→

Medroxyprogesterone Acetate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
71-58-9
PubChem CID
6279
Molecular formula
C24H34O4
Molecular weight
386.5 g/mol
Drug class
Synthetic progestogenester prodrug of medroxyprogesterone
Mechanism of action
Activates progesterone receptors, suppressing gonadotropin secretion and ovulation, thickening cervical mucus and producing endometrial changes. The acetate ester is hydrolysed to medroxyprogesterone; depot formulations provide prolonged release and are not interchangeable with the free parent substance by dose.
Indications / reported uses
  • Contraception with the long-acting intramuscular depot formulation
  • Treatment of secondary amenorrhoea and prevention of endometrial hyperplasia in selected women receiving oestrogen therapy with oral formulations
  • Palliative treatment of selected hormone-responsive cancers in specific high-dose formulations; indication depends on route and formulation

Sources: US DailyMed — DEPO-PROVERA (medroxyprogesterone acetate) · US DailyMed — Oral medroxyprogesterone acetate · FDA product information

Identification source: PubChem record (CID 6279). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Synthetic progestogen; ester prodrug of medroxyprogesterone

Mechanism of action

Activates progesterone receptors, suppressing gonadotropin secretion and ovulation, thickening cervical mucus and producing endometrial changes. The acetate ester is hydrolysed to medroxyprogesterone; depot formulations provide prolonged release and are not interchangeable with the free parent substance by dose.

General use cases

  • Contraception with the long-acting intramuscular depot formulation
  • Treatment of secondary amenorrhoea and prevention of endometrial hyperplasia in selected women receiving oestrogen therapy with oral formulations
  • Palliative treatment of selected hormone-responsive cancers in specific high-dose formulations; indication depends on route and formulation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Medroxyprogesterone Acetate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Medroxyprogesterone Acetate Permitted Daily Exposure (PDE) report (the Medroxyprogesterone Acetate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Medroxyprogesterone Acetate Occupational Exposure Limit (OEL) report (the Medroxyprogesterone Acetate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.